October 21st, 2018

Next
Click here to begin reading
your complementary article

 
Title:
The Significance of Low Anti-Müllerian Hormone Levels in Young Women Undergoing in Vitro Fertilization
Authors:  Caitlin Haswell, M.D., Estil Strawn, Jr., M.D., Aniko Szabo, Ph.D., Joseph Davis, D.O., and Kate D. Schoyer, M.D.
  OBJECTIVE: To determine if young women (aged ≤35 years) with low anti-Müllerian hormone (AMH) levels undergoing their first in vitro fertilization (IVF) cycle have lower pregnancy rates as compared to young women with normal AMH levels.

STUDY DESIGN: Retrospective cohort study.

RESULTS: Thirty-two women with an AMH <1 ng/mL and 130 with an AMH ≥1 ng/mL met study criteria. Patients with AMH <1 ng/mL had higher average FSH levels (8.1 mIU/mL vs. 6.5 mIU/mL) and were slightly older (31.6 vs. 30.4 years). Both groups had comparable numbers of embryos transferred (AMH <1, 1.5±0.6 vs. AMH ≥1, 1.3±0.5). Clinical pregnancy rates per embryo transfer were higher in women with AMH ≥1 ng/mL (47.6% vs. 21.9%). A sensitivity analysis demonstrated lower clinical pregnancy rates in those with AMH <1 ng/mL when excluding those patients with abnormal day 2 FSH or estradiol.

CONCLUSION: AMH levels <1 ng/mL in women ≤35 years old appear to predict lower clinical pregnancy rates in women undergoing IVF, even in the setting of normal day 2-3 ovarian reserve testing. Providers may consider transferring 2 embryos in women ≤35 years with low AMH values. AMH may be used as a sole measure of ovarian reserve in young women if significantly low.
Keywords:  anti-Mullerian hormone, antimullerian hormone, assisted reproductive techniques, assisted reproductive technologies, diminished ovarian reserve, in vitro fertilization
   
   
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from